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CONFLICTS OF INTEREST (COIS)related to the funding ofbiomedical research by phar-maceutical companies and fi-
nancial relationships between research-
ers and pharmaceutical companies have
come under increased scrutiny in re-
cent years.1-3 COIs may influence the
framing of research questions, study de-
sign, data analysis, interpretation of
findings,whether to publish results, and
what results are reported.4,5 Results from
positive trials and from favorable analy-
ses aremore likely to be published than
results unfavorable to sponsors.6-8 Com-
pared with nonindustry-funded trials,
pharmaceutical industry–funded stud-
ies more often yield results or conclu-
sions in support of the sponsor’s
drug,9-16 and authors’ relationshipswith
drug manufacturers have been linked
to favorable assessments of drug effi-
cacy and safety.17-20
As a result, increased emphasis has
been placed on the transparent disclo-
sure of COI. The Consolidated Stan-
dards of Reporting Trials (CONSORT)
guidelines require disclosure of study
funding sources in trial reports.21,22 In-
ternational Committee ofMedical Jour-
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Context Disclosureofconflictsof interest (COIs) frompharmaceutical industrystudyfund-
ing and author-industry financial relationships is sometimes recommended for random-
ized controlled trials (RCTs) published in biomedical journals. Authors of meta-analyses,
however, are not required to report COIs disclosed in original reports of included RCTs.
Objective To investigate whether meta-analyses of pharmacological treatments pub-
lished in high-impact biomedical journals report COIs disclosed in included RCTs.
Data Sources and Study Selection We selected the 3 most recent meta-
analyses of patented pharmacological treatments published January 2009 throughOc-
tober 2009 in each general medicine journal with an impact factor of at least 10; in
high-impact journals in each of the 5 specialty medicine areas with the greatest 2008
global therapeutic sales (oncology, cardiology, respiratory medicine, endocrinology,
and gastroenterology); and in the Cochrane Database of Systematic Reviews.
Data Extraction Two investigators independently extracted data on disclosed study
funding, author-industry financial ties, and author employment from each meta-
analysis, from RCTs included in each meta-analysis, and on whether meta-analyses
reported disclosed COIs of included RCTs.
Results Of 29 meta-analyses reviewed, which included 509 RCTs, only 2 meta-
analyses (7%) reported RCT funding sources; and 0 reported RCT author-industry ties
or employment by the pharmaceutical industry. Of 318 meta-analyzed RCTs that re-
ported funding sources, 219 (69%) were industry funded; and 91 of 132 (69%) that
reported author financial disclosures had 1 or more authors with pharmaceutical in-
dustry financial ties. In 7 of the 29 meta-analyses reviewed, 100% of included RCTs
had at least 1 form of disclosed COI (pharmaceutical industry funding, author-
industry financial ties, or employment), yet only 1 of these 7 meta-analyses reported
RCT funding sources, and 0 reported RCT author-industry ties or employment.
Conclusion Among a group of meta-analyses of pharmacological treatments pub-
lished in high-impact biomedical journals, information concerning primary study fund-
ing and author COIs for the included RCTs were only rarely reported.
JAMA. 2011;305(10):1008-1017 www.jama.com
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nal Editors (ICMJE) guidelines recom-
mend disclosure by authors of study
funding sources and also of author-
industry financial ties.23 There are no
guidelines, however, for the reporting
in meta-analyses of COIs disclosed in
included randomized controlled trials
(RCTs). The Preferred Reporting Items
for Systematic Reviews and Meta-
Analyses (PRISMA) statement re-
quires meta-analysis authors to report
the funding source of a meta-analysis,
but does not address the reporting of
COI from included RCTs.24,25 Meta-
analyses are cited more than any other
study design26 and prioritized in grad-
ing evidence for practice guidelines.27
Meta-analyses supported by the phar-
maceutical industry, through study
funding or author-industry financial
ties, more often reach conclusions that
favor sponsors’ interests than meta-
analyses not linked to industry.28-30
Without documentation in meta-
analyses of COIs from included RCTs,
users ofmeta-analysesmay not have ac-
cess to important information that
could influence their evaluation of the
risk of bias in the evidence reported.
The objective of this studywas to in-
vestigate the extent to which pharma-
ceutical industry funding and author-
industry financial ties or author
employment disclosed in published re-
ports of RCTs of pharmacological in-
terventions are transparently reported
in meta-analyses published in high-
impact general and specialty medicine
journals and the Cochrane Database of
Systematic Reviews. We hypothesized
that few meta-analyses would report




We selected a sample of meta-
analyses published from January 2009
through October 2009 in 3 categories
of high-impact publications: (1) gen-
eralmedicine journals, (2) journals rep-
resenting the top 5 specialty medicine
areas based on 2008 global pharma-
ceutical sales (oncology, cardiology, res-
piratorymedicine, endocrinology, and
gastroenterology),31 and (3) the Coch-
rane Database of Systematic Reviews.
Weprioritized recently publishedmeta-
analyses to reflect current reporting
practices because standards are
evolving.23,24
Within generalmedicine journals,we
selected the 3 most recently published
eligible meta-analyses from each jour-
nal with a 2008 impact factor of at least
10 (New England Journal of Medicine,
JAMA, Lancet, BMJ, Annals of Internal
Medicine, PLoSMedicine),32 with fewer
included if there were not 3 that met
eligibility criteria. Within each spe-
cialty medicine area, we also identi-
fied 3 recently published meta-
analyses. We started with the most
recently publishedmeta-analyses in the
top impact factor journal32 in each spe-
cialty area, then searched the second
highest-rated journal if 3 eligiblemeta-
analyses were not published in the top
journal, and continued to search jour-
nals in declining order of impact fac-
tor until 3 eligible meta-analyses were
obtained.
To obtain our sample, we searched
the MEDLINE database via PubMed
using limits of article type (meta-
analysis) with journal names, supple-
mented by a manual search of each
journal’s table of contents for the term
meta-analysis in article titles or ab-
stracts. For articles published in the
same journal issue, the article with the
highest page number was considered
most recent. Articles published online
ahead of print as of October 31, 2009,
were not eligible. In addition, meta-
analyses from the most recent Coch-
raneDatabase of Systematic Reviews is-
sue (issue 4, 2009) were selected for
review based on randomnumbers gen-
erated in Microsoft Excel until 3 eli-
gible meta-analyses were obtained.
Eligibility Criteria
Eligible meta-analyses (1) included a
documented systematic review of the
literature, (2) statistically combined re-
sults from at least 2 RCTs, (3) did not
include non-RCTs, (4) evaluated the ef-
ficacy or harm of a drug or class of drug
against an alternative treatment (eg, pla-
cebo, alternative drug), and (5) in-
cluded at least 1 drug in the interven-
tion or comparison study groups that
was under patent in the United States
at the time of publication based on the
electronic US Food and Drug Admin-
istration Orange Book.33 A drug was
classified as under patent if any aspect
of the active ingredient (eg, dosage,
route, strength)was protected by anun-
expired patent. We selected meta-
analyses with at least 1 drug under
patent in order to restrict the sample
to drugs of potentially high economic
importance to pharmaceutical compa-
nies. Meta-analyses that investigated
biologics or that investigated a combi-
nation of pharmacological and non-
pharmacological interventions (eg, psy-
chotherapy) were included if a drug
intervention alone was assessed as a
study group.
If either of 2 reviewers indepen-
dently deemed a retrieved meta-
analysis to be potentially eligible based
on title and abstract review, then a full-
text reviewwas conducted. Full-text re-
viewswere conducted independently by
2 reviewers, 1 meta-analysis at a time
in reverse temporal sequence until 3 eli-
gible articles were obtained from each
general medicine journal, each spe-
cialty medicine area, and the Coch-
rane Database of Systematic Reviews.
Chance-corrected agreement between
reviewers was assessed with the Co-
hen  statistic with any disagreements
resolved by consensus. Translators as-
sisted reviewers to evaluate non-
English titles, abstracts and articles and
in data extraction.
Data Extraction
Two investigators independently re-
viewed all meta-analyses and in-
cluded RCTs, including disclosure
statements, article texts and tables, au-
thor bylines and acknowledgments, and
all online journal supplements (see
eAppendix for data extraction forms at
http://www.jama.com) to identify (1)
disclosure of COIs (study funding, au-
thor-industry financial ties or employ-
ment) from each selected meta-
analysis; (2) disclosure of COIs for all
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RCTs included in each meta-analysis;
and (3) to determine whether or not
disclosed COIs from included RCTs
were reported inmeta-analyses. For in-
cluded RCTs published only as ab-
stracts, we verified whether a separate
disclosure section was published and
extracteddata, as appropriate. Formeta-
analyses, we also determined whether
a quality or risk of bias assessment of
included RCTs was conducted and, if
so, the instrument used.
Study funding sources for meta-
analyses and included RCTs were clas-
sified as pharmaceutical industry, non-
industry (eg, public granting agency,
private not-for-profit granting agency),
combined pharmaceutical industry and
nonindustry, nonindustry with drug
supplied by pharmaceutical industry
(RCTs only), no study funding, or not
reported. Studies reported as funded “in
part” by the pharmaceutical industry
with no other indication of funding
source were coded as industry-funded.
Study funding included provision of fi-
nancial support, resources (eg, statisti-
cal analyses), or inclusion of study per-
sonnel beyond those listed as authors.
Author financial ties to industrywere
defined per theOctober 2009 version of
the ICMJE Uniform Disclosure
Form for Potential Conflicts of Inter-
est23 and included current or former
board membership, current or former
consultancy, former industry employ-
ment, equity holdings (eg, stock,
stock options), expert testimony,
gifts, patents (planned, pending, or
issued), payment for manuscript
preparation, other research funding, roy-
alties, speaker fees/payment for presen-
tation development, travel reimburse-
ment, or unspecified honoraria, as
disclosed in the article. If an article did
not contain a disclosure statement or ac-
knowledgments, author-industry finan-
cial tieswere coded as not reported. Au-
thorship by individuals employedby the
pharmaceutical industry at the time of
article publication was coded sepa-
rately as industry employment.
If a meta-analysis included citations
to multiple articles reporting on the
same RCT, each article was reviewed
and COIs were coded as present if
reported in any of the cited articles. For
meta-analyses that included RCTs of
bothpharmacological andnonpharma-
cological interventions, onlyRCTs that
assessed a pharmacological interven-
tion alone as a study group were
reviewed. Any discrepancies in data
extractionwere resolved by consensus.
Corresponding authors of meta-
analyses were contacted via e-mail (as
many as 3 attempts) to determine
whether data extraction protocols in-




A total of 133 potentially eligible
titles/abstracts were reviewed, includ-
ing 52 from general medicine jour-
nals, 70 from specialty medicine jour-
nals, and 11 from the Cochrane
Database of Systematic Reviews. Of
these, 93 were excluded after title/
abstract review and 11 after full-text
review, leaving 29 eligible meta-
analyses that were included in the
review (eTable 1).34-62 The 29 meta-
analyses included11 fromgeneralmedi-
cine journals (3 each from JAMA, Lan-
cet, and BMJ; 2 from Annals of Internal
Medicine; 0 fromNewEngland Journal of
MedicineorPLoSMedicine), 15 fromspe-
cialtymedicine journals, and 3 from the
Cochrane Database of Systematic Re-
views. Impact factors of journalswith in-
cludedmeta-analyses ranged from 12.2
to 31.7 in generalmedicine, 13.3 to 17.2
in oncology, 8.9 to 14.6 in cardiology,
5.2 to 5.5 in respiratory medicine, 6.4
to 7.3 in endocrinology, 7.4 to 9.8 in gas-
troenterology, and 5.2 for the Coch-
rane Database of Systematic Reviews.
Cohen  for chance-corrected agree-
ment on inclusion/exclusion decisions
was 0.94.
As shown in TABLE 1 and TABLE 2,
the 29 selected meta-analyses evalu-
ated a broad spectrum of pharmaco-
logical interventions, including 21 on
treatment efficacy, 3 on harms, and 5
on both efficacy and harms. Between 2





As shown in Table 1 and Table 2, 0 of
the 29 selected meta-analyses re-
ported being funded by the pharma-
ceutical industry. Fourteen (48.3%) re-
ported nonindustry funding, 4 reported
no study funding (13.8%), and the
funding source of 11 (37.9%) was not
reported. At least 1 author of 16 of the
29 meta-analyses (55.2%) reported at
least 1 financial tie to the pharmaceu-
tical industry, all of the authors of 12
of the meta-analyses (41.4%) reported
0 financial ties to the pharmaceutical
industry, and author financial ties were
not reported in 1meta-analysis (3.4%).
Specific types of author ties to the phar-
maceutical industry for each meta-
analysis are shown in eTable 2. Only 1
of the 29 meta-analyses listed authors





The 29 selected meta-analyses syn-
thesized data from a total of 509
RCTs. As shown in TABLE 3, 62.5%
(318 of 509) of included RCTs
reported funding source. Of these,
68.9% (219 of 318) were funded in
part or whole by the pharmaceutical
industry; 30.5% (97 of 318) by non-
industry funding sources, including
28 RCTs in which a study drug was
supplied by the pharmaceutical
industry; and less than 1% (2 of 318)
reported that the trial received no
funding. Characteristics of the 509
included RCTs, including COI data,
are presented in eTable 3.
Author financial disclosureswere re-
ported in only 25.9% (132 of 509) of
included RCTs. Among these, 68.9%
(91 of 132) reported 1 or more au-
thors having financial ties to the phar-
maceutical industry. Author affilia-
tions were reported in 94.7% of
included RCTs (482 of 509), includ-
ing 26.1% (126 of 482) with at least 1
author employed by the pharmaceuti-
cal industry.
REPORTING CONFLICTS OF INTEREST IN META-ANALYSES
1010 JAMA, March 9, 2011—Vol 305, No. 10 (Reprinted) ©2011 American Medical Association. All rights reserved.
 at Rijksuniversiteit Groningen on March 10, 2011jama.ama-assn.orgDownloaded from 
Reporting of Disclosed COIs From
RCTs Included in Meta-analyses
As shown in Table 3, only 2 of the 29
selectedmeta-analysesreportedthefund-
ing source of included RCTs.47,62 One
listedRCTfundingsources inatable foot-
note47 and the other in the Characteris-
ticsofStudiestablethat followedthemain
documentandreferences.62Neithermen-
tioned RCT funding sources in the col-
umn of a core table, in the text, or in an
assessmentofpotentialbias.Bothof these
meta-analyses47,62 reported nonindus-




a link to the pharmaceutical industry.47
None of the 29 meta-analyses reported
author-industry financial tiesoremploy-
ment of included RCTs.
Of the 29 meta-analyses, 25 as-
sessed quality or risk of bias in in-
cluded RCTs. One of the meta-
analyses that reported the funding
source of included RCTs47 used an ad
hocmethod to assess study quality that
did not include an assessment of study
funding. Fivemeta-analyses34,44,60-62 used
at least 3 of the 6 domains from the
Cochrane Risk of Bias tool, which does
not produce a single quality score, but
rather provides ratings for individual
risk components.63 Only 1 of the 5
meta-analyses62 reported the funding
source of included RCTs, but it did not
include this information in the assess-
ment of risk of bias.
In 7 of 29 meta-analyses (Table 3),
100% of included RCTs disclosed at
least 1 form of COI in the original RCT
publications.37,38,40,44,47,54,60 In 4 of these
7 meta-analyses,37,44,54,60 100% of in-
cluded RCTs that reported study fund-
ing were funded by the pharmaceutical
industry. Only 1 of the 7 meta-
analyses, however, provided informa-
tion on study funding of included
RCTs,47 and that was done in a table
footnote.
Twenty-seven of 29 meta-analysis
authors provided information on data
extraction protocols. Two recorded
and reported RCT funding sources47,62;
5 recorded, but did not report funding
sources; and 20 did not record fund-
ing sources. Only 2 of the 27 meta-



































Efficacy Nonindustry 1/7 0/7
Berger, JAMA
(1975-2008)35





Efficacy None 3/4 0/4
Häuser, JAMA
(1986-2008)36
18 18 FMS Antidepressants Placebo Efficacy Nonindustry 3/4 0/4
Sin, Lancet
(1998-2009)37





Harm Nonindustry 7/8 3/8
Ray, Lancet
(1998-2009)38














































6 6 Bell palsy Steroids plus
antivirals
Steroids Efficacy None 1/6 0/6
Hayward, BMJ
(1993-2008)43
8 8 Sore throatd Corticosteroids Placebo or
control









Efficacy None 0/6 0/6
Abbreviations: COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; FMS, fibromyalgia syndrome; PAD, peripheral artery disease.
aAll included meta-analyses were published in 2009; review date range indicates the publication dates of articles reviewed for each meta-analysis.
bDetails of author-industry financial ties and pharmaceutical author industry employment are provided in eTable 2.
cA combined formulation of aspirin and dipyridamole was under patent.
dStudy included adults and children.
eStudy included only children.
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analyses recorded RCT author-
industry financial ties, but neither
published this information.
COMMENT
The main finding of this study is that
with fewexceptions, informationonCOI
disclosed in RCTs is not reportedwhen
RCT data are combined in meta-
analyses. Pharmaceutical industry fund-


























































17 17 Cancer Bevacizumab Placebo or
controlc





50 50 Cardiac surgery Corticosteroid
prophylaxis
Placebo or control Efficacy Nonindustry 0/2 0/2
De Luca, J Am
Coll Cardiol
(2004-2008)49

























62d 59 Asthma Formoterol Placebo or
non-LABA
drug
Harm Nonindustry 1/5 0/5
Sindi, Chest
(1994-2006)52
32 32 Asthmae (1) LABAs
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ingwas present in 69%of the RCTs that
disclosed funding. However, only 2 of
29 meta-analyses provided informa-
tion on funding sources of included
RCTs.None reported author-industry fi-
nancial ties or employment disclosed in
the original RCT publications. The 2
meta-analyses that reported RCT fund-
ing sources provided this information in
a table that followed the main docu-
ment and references62 and in a table foot-
note,47 neither of which are typically re-
viewed by the average reader. Neither
meta-analysis described sources ofCOIs
in a core table, in the text, or in an analy-
sis of potential sources of bias.
There is general agreement on the
need for complete and transparent dis-
closure of COI in biomedical re-
search.21-23 The results of the present
study highlight a major gap in the re-
porting of COIs and suggest that, with-
out a formal reportingpolicy,COIs from
RCTs are unlikely to be reported when
results are synthesized in meta-
analyses. ThePRISMAstatement should
be updated to require authors of meta-
analyses to report funding sources of in-
cluded RCTs or report that funding
sourceswere not disclosed. Study fund-
ingwas disclosed in the original reports
of approximately two-thirds of RCTs in
this review.
In addition to information on study
funding, consumers of research, includ-
ing patients and physicians, want re-
searcher financial ties to industry to be
disclosed64 and consider author-
industry financial ties in assessing the
quality of research evidence.64-66 The au-
thors of the PRISMA statement should
also consider recommending thatmeta-
analyses report author-industry finan-
cial ties disclosed in included RCTs or
report that therewasnodisclosure state-
ment. Although author-industry ties are
less frequently reported than study fund-
ing sources inpublished reports ofRCTs
included in meta-analyses, the propor-
tion of RCTs reporting author-industry
financial tieswill likely increasewith the
recent introduction of ICMJE disclo-
sure guidelines. The nature and extent
of author-industry ties disclosed inRCTs
are complex. However, coding the pro-
portion of authorswith disclosed indus-
try financial tieswouldnotbeagreatbur-
den and would flag studies with COIs
fromauthor-industry financial ties for in-
terested readers.
Authors of meta-analyses are ex-
pected to transparently assess and inter-
pret potential sources of bias from in-
cluded studies that could influence
outcomes. Items included in quality or
risk of bias assessment tools (eg, se-
quencegeneration, blinding) are increas-
ingly selected based on empirical evi-
dence of an association with bias,
including themechanism, direction, and
likely magnitude of possible bias.63,67
Meta-analysis authors should docu-
ment that they have evaluated all poten-
tially relevant sources of bias, whether
or not a particular source of possible bias
is present in the studies reviewed and
whether or not the magnitude of bias is
expected to be large in comparisonwith


































































Placebo or control Efficacy Nonindustry 0/3 0/3
Abbreviations: DM, diabetesmellitus; HTN, hypertension; IBS, irritable bowel syndrome; ICS, inhaled corticosteroids; LABA, long-acting-agonist; MAO-B,monoamine oxidaseB; NSCLC,
non-small cell lung cancer; PUFA, polyunsaturated fatty acid; STEMI, ST-segment elevation myocardial infarction.
aAll included meta-analyses were published in 2009; review date range indicates the publication dates of articles reviewed for each meta-analysis.
bDetails of author-industry financial ties and pharmaceutical author industry employment are provided in eTable 2.
cComparison arm (control chemotherapy treatment) included patented drug.
dFifty-nine citations reported the results of 62 RCTs (3 citations each reported the results of 2 RCTs).
eStudy included adults and children.
fMeta-analysis reported that 30 RCTs were included. However, 1 RCT was listed twice.
gMeta-analysis included 32 RCTs in total, of which 13 were RCTs of pharmacological interventions and 19 were RCTs of psychological treatments.
hMeta-analysis included 26 RCTs in total, of which 12 were RCTs of pharmacotherapy alone vs endoscopic therapy and 14 were RCTs of pharmacotherapy plus endoscopic therapy vs
endoscopic therapy and did not assess the pharmacological intervention alone.
iMeta-analysis included 42 RCTs in total, of which 19 were RCTs of pharmacotherapy alone vs endoscopic therapy and 23 were RCTs that compared endoscopic therapies.
jEighteen citations reported the results of 19 RCTs (1 citation reported the results of 2 RCTs).
kMeta-analysis reference list included 103 citations. However, 3 included citations were each listed twice in reference list.
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Table 3. Disclosure and Reporting in Meta-analyses of RCT Funding Source, Author Financial Ties to the Pharmaceutical Industry, and Author






































18 No No 6/18 2/6 2/18 2/2 17/18 0/17 3/18 Cochrane
Berger,
JAMA35
18 No No 9/18 5/9 2/18 0/2 15/18 3/15 7/18 Jadad
Häuser,
JAMA36
18 No No 12/18 9/12 3/18 3/3 18/18 8/18 13/18 Jadad, Van
Tulder
Sin, Lancet37 7 No No 6/7 6/6 3/7 2/3 7/7 6/7 7/7 Jadad
Ray, Lancet38 5 No No 5/5 4/5 4/5 4/4 4/5 1/4 5/5 None
Heerspink,
Lancet39








7 No No 5/7 0/5 1/7 0/1 5/7 0/5 0/7 Ad hoc
Quant, BMJ42 6 No No 4/6 2/4 3/6 2/3 6/6 0/6 3/6 Jadad
Hayward,
BMJ43
8 No No 1/8 0/1 1/8 0/1 8/8 0/8 0/8 Ad hoc
Shun Shin,
BMJ44
7 No No 7/7 7/7 3/7 3/3 6/7 6/6 7/7 Cochrane
Soon, J Clin
Oncol45
13 No No 6/13 4/6 3/13 1/3 12/13 2/12 6/13 Ad hoc
Di Maio, J Clin
Oncol46




17 Yes No 12/17 9/12 17/17 16/17 17/17 9/17 17/17 Ad hoc
Ho and Tan,
Circulation48
50 No No 19/50 4/19 6/50 0/6 50/50 0/50 4/50 Ad hoc
De Luca, J Am
Coll
Cardiol49




31 No No 29/31 29/29 16/31 14/16 25/31 9/25 29/31 Jadad
Wijesinghe, Eur
Respir J51
62 No No 38/62 37/38 10/62 10/10 58/62 39/58 51/62 None
Sindi, Chest52 32 No No 24/32 18/24 5/32 5/5 32/32 5/32 22/32 Jadad, ad hoc
Tassinari,
Chest53








29 No No 20/29 8/20 8/29 2/8 29/29 1/29 9/29 Ad hoc
Lasserson,
Diabetologia56
22 No No 20/22 19/20 7/22 7/7 22/22 14/22 20/22 Jadad, ad hoc








19 No No 8/19 2/8 3/19 0/3 19/19 1/19 2/19 Ad hoc
(continued)
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other likely sources of bias. Risk of bias
ratings for various domains are used by
meta-analysts as stratification factors in
sensitivity analyses or more qualita-
tively. For instance,meta-analystsmight
note that all RCTs in a given reviewhave
significant design shortcomings and a
high risk of bias.
COIs from pharmaceutical industry
study funding and author-industry fi-
nancial ties meet the empirical criteria
typically used to select other potential
sources of bias for inclusion in evi-
dence quality and risk of bias assess-
ment tools. Pharmaceutical industry
funding and author-industry financial
ties are associatedwith a bias toward fa-
vorable results evenwhencontrolling for
other study characteristics.12,13 Based on
empirical evidenceof bias related toCOI,
an Agency for Healthcare Research and
Quality systematic review of tools used
to rate evidence quality67 included the
category funding or sponsorship as a key
evaluationdomainand rated toolshigher
if they included an assessment of poten-
tial bias fromindustry sponsorship. Simi-
larly, the recently developed Assess-
mentofMultiple SystematicReviews tool
for grading the methodological quality
of systematic reviews includes a score for
whetherCOIs from included studies are
clearly described.68
Meta-analysts should evaluate the
potential for bias due to pharmaceutical
industry study funding and author-
industry financial tiesaspartof theirstan-
dardriskofbiasassessment.Aswithother
potential sourcesofbias, results fromthis
domain should be transparently docu-
mented and used in sensitivity analyses
orqualitatively.For instance,asetofposi-
tive results from industry-funded trials
would likely be interpreted with more
confidence if corroborated by at least 1
studywith similar findings that was not
industry-funded. The funding source
and thus the risk of bias due to industry
funding will be unclear for some stud-
ies, such as those conductedprior to the
adoptionof guidelines for declaring this
type of information.
Although some risk of bias assess-
ment tools include a domain for study
funding source, most do not.67 Cur-
rently, the Cochrane Collaboration’s
Risk of Bias tool includes an optional
“other sources of bias” domain,63 which
meta-analysts could use to include in-
formation on COIs. We recommend
that the Cochrane Collaboration con-
sider formalizing the requirement to as-
sess potential bias from COIs.
Several limitations should be consid-
ered in interpreting results from this
study. First, the studywas not designed
to assesswhether reporting ofCOI from
RCTs included inmeta-analyseswas re-
lated to the quality of meta-analyses or
whether COIs from included RCTs
influenced the results of the meta-
analyses reviewed. However, the moti-
vation to conduct this study was based
on extensive research that has shown
that COIs can influence the results
and conclusions of bothRCTs andmeta-
analyses.11,13,14,28-30 Second, we re-
viewed a relatively small sample ofmeta-
analyses fromhigh-impact journals, and
it is not clear to what degree these re-
sults can be generalized to other areas of
medicine or to lower-impact journals.
None of the 29 meta-analyses reviewed
reported funding from the pharmaceu-
Table 3. Disclosure and Reporting in Meta-analyses of RCT Funding Source, Author Financial Ties to the Pharmaceutical Industry, and Author







































































Abbreviations: NA, not applicable; RCT, randomized controlled trial.
aNumerator is the number of RCTs that reported; denominator is the number of RCTs in the meta-analysis.
bNumerator is the number of RCTs with conflict of interest; denominator is the number of RCTs that reported.
cQuality or risk of bias tool used by meta-analysis authors to assess included RCTs.
dAbridged version of Cochrane Risk of Bias tool, including only 4 of 6 domains.
eAbridged version of Cochrane Risk of Bias tool, including only 3 of 6 domains.
f It was not possible to report a combined proportion of trials reported since different numbers of meta-analyses provided different information for funding source, author financial ties, and
author employment.
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tical industry, for instance, and it is pos-
sible that we undersampled industry-
funded meta-analyses. However, given
that only 2 of 29 (7%) meta-analyses
mentionedCOIs from includedRCTs, it
is likely that the main findings of the
study are generalizable. Finally, the ex-
act nature ofCOIs in includedRCTs (eg,
amountof industry funding, roleof fund-
ing source) was not assessed. However,
this information is not typically avail-
able and studies thathave identified links
between pharmaceutical industry fund-
ing and study outcomes have similarly
reliedupondichotomous coding.10,12,15,16
In summary, this study found that
meta-analyses of pharmacological in-
terventions published in high-impact
medical journals rarely reported the
funding sources or author-industry fi-
nancial ties of included RCTs, even
when these sources of COIs were dis-
closed in RCT reports. PRISMA should
require the reporting of study funding
sources and author-industry financial
ties of RCTs inmeta-analyses, and this
information should be included in risk
of bias assessments.
Risk of bias assessment in meta-
analyses due to COI or other sources of
potential bias in included RCTs is im-
perfect, anddisclosure is anecessary first
step, but not sufficient tomitigate the ef-
fects of COI on biomedical research.69
Nonetheless, if COIs disclosed by au-
thors of RCTs are not reported when
RCTs are synthesized in meta-analyses,
efforts to achieve greater transparency in
biomedical research through disclo-
sure requirementsmay be less effective.
Given that COIs are prominent in bio-
medical research and have been empiri-
cally linked to bias, it is the responsibil-
ity of authors of meta-analyses to
transparently document for readers their
efforts to evaluate the likely influence of
COI on meta-analysis outcomes.
If COIs from included RCTs are not
acknowledged inmeta-analyses, 1 of 2
messages may be sent to readers—the
first is that the authors of the meta-
analysis have not consideredCOI in in-
cluded studies, which leaves readers in
a position of not knowing how to in-
terpret possible biases that may have
arisen because of COI in the original
RCTs; and the second possible mes-
sage is that the meta-analysts have in
fact assessed the risk of bias related to
COI in the original RCTs, concluded
that the COIs did not create any bi-
ases, and therefore have chosen not to
comment on the COIs. This interpre-
tationmay lead readers to trust the con-
clusions of a meta-analysis when they
potentially should not. In either case,
without acknowledgment of COI due
to industry funding or author-
industry financial ties from RCTs in-
cluded in meta-analyses, readers’ un-
derstanding and appraisal of the
evidence from themeta-analysismay be
compromised.
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